Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine) in the Treatment of Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 May 2017
At a glance
- Drugs Sargramostim (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.